Yoritaka A - Search Results

1

Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study.

Nishikawa N, Hatano T, Nishioka K, Ueno SI, Saiki S, Nakamura R, Yoritaka A, Ogawa T, Shimo Y, Sako W, Shimura H, Furukawa Y, Kamei T, Ishida T, Hattori N; J-SILVER study group. Nishikawa N, et al. Among authors: yoritaka a. J Neurol Sci. 2024 Jun 15;461:123051. doi: 10.1016/j.jns.2024.123051. Epub 2024 May 17. J Neurol Sci. 2024. PMID: 38788287 Free article.

2

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Yoritaka A, et al. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701. doi: 10.1073/pnas.93.7.2696. Proc Natl Acad Sci U S A. 1996. PMID: 8610103 Free PMC article.

3

An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease.

Yoritaka A, Hattori N, Mori H, Kato K, Mizuno Y. Yoritaka A, et al. J Neurol Sci. 1997 May 29;148(2):181-6. doi: 10.1016/s0022-510x(96)05339-7. J Neurol Sci. 1997. PMID: 9129114

4

Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. Short communication.

Yoritaka A, Hattori N, Yoshino H, Mizuno Y. Yoritaka A, et al. J Neural Transm (Vienna). 1997;104(11-12):1313-7. doi: 10.1007/BF01294732. J Neural Transm (Vienna). 1997. PMID: 9503277 Clinical Trial.

5

A microdeletion of D6S305 in a family of autosomal recessive juvenile parkinsonism (PARK2).

Matsumine H, Yamamura Y, Hattori N, Kobayashi T, Kitada T, Yoritaka A, Mizuno Y. Matsumine H, et al. Among authors: yoritaka a. Genomics. 1998 Apr 1;49(1):143-6. doi: 10.1006/geno.1997.5196. Genomics. 1998. PMID: 9570960

6

A large Japanese family with Machado-Joseph disease: clinical and genetic analysis.

Yoritaka A, Nakagawa-Hattori Y, Hattori N, Kitahara A, Mizuno Y. Yoritaka A, et al. Acta Neurol Scand. 1999 Apr;99(4):241-4. doi: 10.1111/j.1600-0404.1999.tb07354.x. Acta Neurol Scand. 1999. PMID: 10225355

7

Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences?

Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Yoritaka A, et al. Eur Neurol. 2009;61(3):164-70. doi: 10.1159/000189269. Epub 2009 Jan 8. Eur Neurol. 2009. PMID: 19129703

8

Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia.

Kawanabe T, Yoritaka A, Shimura H, Oizumi H, Tanaka S, Hattori N. Kawanabe T, et al. Among authors: yoritaka a. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):284-7. doi: 10.1016/j.pnpbp.2009.11.019. Epub 2009 Dec 3. Prog Neuropsychopharmacol Biol Psychiatry. 2010. PMID: 19948198

9

Nonmotor Symptoms in Patients with PARK2 Mutations.

Yoritaka A, Shimo Y, Shimo Y, Inoue Y, Yoshino H, Hattori N. Yoritaka A, et al. Parkinsons Dis. 2011 Jan 13;2011:473640. doi: 10.4061/2011/473640. Parkinsons Dis. 2011. PMID: 21317980 Free PMC article.

10

Cerebral infarction in a young man using high-dose anabolic steroids.

Shimada Y, Yoritaka A, Tanaka Y, Miyamoto N, Ueno Y, Hattori N, Takao U. Shimada Y, et al. Among authors: yoritaka a. J Stroke Cerebrovasc Dis. 2012 Nov;21(8):906.e9-11. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.013. Epub 2011 Sep 8. J Stroke Cerebrovasc Dis. 2012. PMID: 21903417

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters